Biosimilars. (1/20)

Propositional debate on biosimilar enoxaparin in Brazil. (2/20)

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? (3/20)

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. (4/20)

Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist. (5/20)

Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. (6/20)

The emergence of biosimilar insulin preparations--a cause for concern? (7/20)

Biosimilars: what clinicians should know. (8/20)

• 1
• 2
• 3